The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The most important decision for community oncologists when managing newly diagnosed myeloma
In this video, Amrita Krishnan, MD, City of Hope, Duarte, CA, comments on the most important decision a community oncologist must make when managing a patient with newly diagnosed multiple myeloma (MM): selecting an optimal induction regimen. She highlights that the goal is to achieve a deep, durable first remission and recommends early involvement of a myeloma specialist. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
